Dr RR Baliga's "Got Knowledge Doc" Podkast

Dr RR Baliga's "Got Knowledge Doc" Podkast

By Dr RR Baliga, MD, MBAScienceEducationNatural Sciences
Download on the App Store

Dr RR Baliga's "Got Knowledge Doc" Podkast episodes

  • Great Doctors Series: Pietro d'Abano⚕️ The Great Reconciler

    🔥 Medicine, Heresy & the Stars: Pietro d'Abano

    Meet Pietro d'Abano (c.1257–1315/16)—physician, philosopher, astrologer, and one of medieval medicine's great intellectual boundary-crossers. 🩺📚

    Drawing on Aristotle, Avicenna and Averroes, his Conciliator tried to reconcile medicine with natural philosophy. His willingness to question accepted explanations eventually collided with the Inquisition. ⚖️🔥

    A fascinating reminder that medical progress has always depended on curiosity—and sometimes courage.

    🎙️ Great Doctors Series | Where Curiosity Meets Clarity!

    2 min
  • 🔥 Drop Aspirin? Not So Fast in High-Ischemic-Risk Patients

    🩸 Drop aspirin after 12 months? A-CLOSE says: not so fast. In 3,203 high-ischemic-risk patients after drug-eluting stenting, clopidogrel alone was noninferior to extended DAPT for net clinical events (5.0% vs 5.1%).

    But beneath that reassuring composite was a striking trade-off: ischemic events were higher with clopidogrel alone (3.7% vs 1.6%; HR 2.33), while bleeding was lower (1.8% vs 4.1%; HR 0.43).

    ⚖️ The lesson: "noninferior" does not mean clinically interchangeable. Individualize ischemic versus bleeding risk. ❤️

    3 min
  • 💉 Lysis Before Collapse: PRAGUE-26 Changes the PE Conversation

    🫁 Stable—but not safe. Should we intervene before patients crash?

    PRAGUE-26 randomized 558 patients with intermediate-high–risk acute pulmonary embolism to catheter-directed low-dose alteplase + anticoagulation or anticoagulation alone. The 7-day composite of death, recurrent PE, or cardiorespiratory decompensation/collapse fell from 6.8% to 0.7% (RR 0.10; P—mainly through fewer episodes of decompensation. 🎯

    Major bleeding was not increased, although 2 intracranial hemorrhages occurred with thrombolysis. 🩸

    💡 The emerging paradigm: prevent the crash rather than rescue it.

    3 min
  • 💊 Food as Medicine—from Beneath the Waves

    🦪 Small Creatures, Mighty Nutrition, Global Impact

    Could aquatic invertebrates help close the global micronutrient gap? 🌊 A fascinating Nature study finds that current production supplies the equivalent annual requirements of vitamin B12 and selenium for >5 billion people—and copper, omega-3 fatty acids, iodine and zinc for >1 billion. 🦐

    💡 Bivalves are particularly rich in iron, iodine, zinc and B12. But nutrition on paper is not nutrition on the plate: sustainability, safety, access, affordability and bioavailability matter.

    Tiny creatures. Enormous nutritional potential. 🌍

    3 min
  • 🔌 Unplugging Pulmonary Hypertension: Can Denervation Change Heart Failure?

    🫀 Cut the Signal, Cut the Risk?

    Could pulmonary-artery denervation change the trajectory of heart failure–related pulmonary hypertension?

    In PADN-HF-PH, 264 symptomatic patients were randomized to denervation + guideline-directed medical therapy or medical therapy alone. Clinical worsening at 2 years: 25.7% vs 51.5% (HR 0.49; P=0.006). ⚡

    A provocative concept: pulmonary sympathetic overactivity may be a modifiable therapeutic target. 🎯

    But no sham control, China-only enrollment, and mortality benefit remains unproven

    3 min
  • 🧬 Semaglutide, Senescence & Survival: Can GLP-1 Slow Ageing?

    🧬 Could semaglutide do more than treat obesity and diabetes?

    A fascinating study in aged female mice suggests that late-life semaglutide may act partly as a calorie-restriction mimetic—improving cognition, physical function and glucose control while attenuating multiple hallmarks of ageing. 🐭⏳

    Most strikingly, median lifespan increased from 742 to 834 days. The biology implicates nutrient sensing, NAD⁺–sirtuin and insulin–IGF1 pathways.

    3 min
  • 30% Fewer Cardiovascular Events: Statins Still Matter After age 70

    🫀 Should we start a statin after age 70? STAREE delivers an important answer.

    In 9,971 adults ≥70 without cardiovascular disease, diabetes, or dementia, atorvastatin 40 mg reduced major cardiovascular events by 30% over 5.9 years (HR 0.70; NNT 37).

    💊 Yet it did not prolong disability-free survival (HR 0.94). The benefit was driven largely by fewer myocardial infarctions and coronary revascularizations.

    🎯 Take-home: age alone should not close the door on cardiovascular prevention—but preventing events is not the same as extending healthy life.

    2 min
  • ✍️ The Great Translator: How Constantine of Africa Carried Medicine Across Cultures

    🌍 The Monk, the Manuscripts, the Medical Bridge

    How did Arabic medical knowledge reach medieval Europe? 📚🩺

    Meet Constantine the African (c. 1010–1087)—North African physician, multilingual translator, and Benedictine monk at Monte Cassino. His Latin translations of major Arabic medical works helped transmit centuries of scholarship to Salerno and beyond.

    🌉 His enduring lesson: medicine advances when knowledge crosses borders.

    🎙️ Great Doctors Series — Dr RR Baliga's Podkast for the Kurious Doc. Where Curiosity Meets Clarity!

    3 min
  • 🫀 Plaque in Your 20s? The REACT Wake-Up Call

    🫀 Atherosclerosis doesn't wait for middle age. In the REACT study of 16,808 adults without known ASCVD, silent plaque was found in 57.1% overall—and even in 8.7% of men and 6.7% of women aged 18–29.

    Plaque burden rose dramatically with age and increasingly involved multiple arterial territories. 🚨

    Even more provocative: conventional 10-year risk classification identified only a minority with existing silent disease.

    Low predicted risk does not necessarily mean plaque-free arteries. 🔍 Prevention may need to think younger—and earlier.

    3 min
  • 🛡️ One Risk Factor in Atrial Fibrillation: Is It Time for a DOAC?

    🫀 AF + just one stroke-risk factor: anticoagulate or not?

    The SINGLE-AF randomized trial tackled this common clinical gray zone. At 24 months, the composite of stroke, systemic embolism, major bleeding, or cardiovascular death occurred in 0.5% with a DOAC vs 1.5% without anticoagulation (HR 0.31; P=0.03). 🎯

    ⚠️ Only 17 primary events occurred, so the effect estimate remains imprecise.

    Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.pdf

    💡 Takeaway: SINGLE-AF strengthens the case for DOAC therapy in selected intermediate-risk AF patients—but individualized decision-making remains essential.

    3 min

About Dr RR Baliga's "Got Knowledge Doc" Podkast

From the publisher's feed

"Got Knowledge Doc" Podkast with Dr. RR Baliga

More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast

This Week in Cardiology by Medscape

This Week in Cardiology

893 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,351 Listeners

The Mel Robbins Podcast by Mel Robbins

The Mel Robbins Podcast

19,270 Listeners